Ginglen JG, Doyle MQ. Immunization. In: Stat Pearls. Treasure Island (FL): StatPearls Publishing; 2023.

Hajdu SI. A note from history: Landmarks in history of cancer, part 1. Cancer. 2011;117(5):1097–102.

Article  PubMed  Google Scholar 

Dobosz P, Dzieciątkowski T. The Intriguing History of Cancer Immunotherapy. Front Immunol. 2019;10:2965.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oiseth SJ, Aziz MS. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. J Cancer Metastasis Treat. 2017;3:250–61.

Article  CAS  Google Scholar 

Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases 1893. Clin Orthop Relat Res. 1991;262:3–11.

Google Scholar 

Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–3.

Article  CAS  PubMed  Google Scholar 

Decker WK, da Silva RF, Sanabria MH, Angelo LS, Guimarães F, Burt BM, et al. Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models. Front Immunol. 2017;8:829.

Article  PubMed  PubMed Central  Google Scholar 

Beasley RP. Hepatitis B Virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61(10):1942–56.

Article  CAS  PubMed  Google Scholar 

Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299–308.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci. 2013;1284(1):1–5.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28.

Article  PubMed  PubMed Central  Google Scholar 

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

Article  CAS  PubMed  Google Scholar 

Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38:255.

Article  PubMed  PubMed Central  Google Scholar 

Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tormoen GW, Crittenden MR, Gough MJ. Role of the immunosuppressive microenvironment in immunotherapy. Adv Radiat Oncol. 2018;3:520–6.

Article  PubMed  PubMed Central  Google Scholar 

Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front Pharmacol. 2022;13:868695.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thomas DA, Massagué J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8(5):369–80.

Article  CAS  PubMed  Google Scholar 

Halle S, Halle O, Förster R. Mechanisms and dynamics of T cell-mediated cytotoxicity in vivo. Trends Immunol. 2017;38(6):432–43.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Guan XY, Jiang P. Cytokine and chemokine signals of T-cell exclusion in tumors. Front Immunol. 2020;11:594609.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paston SJ, Brentville VA, Symonds P, Durrant LG. Cancer vaccines, adjuvants, and delivery systems. Front Immunol. 2021;12:627932.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135–46.

Article  CAS  PubMed  Google Scholar 

Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol CVI. 2011;18(1):23.

Article  CAS  PubMed  Google Scholar 

Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360–78.

Article  CAS  PubMed  Google Scholar 

Weon JL, Potts PR. The MAGE protein family and cancer. Curr Opin Cell Biol. 2015;37:1–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 1998;58:4895–901.

CAS  PubMed  Google Scholar 

Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst. 1997;89:293–300.

Article  CAS  PubMed  Google Scholar 

Lam KW, Li CY, Yam LT, Sun T, Lee G, Ziesmer S. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate. 1989;15:13–21.

Article  CAS  PubMed  Google Scholar 

Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009;27:4685–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Srivastava PK. Neoepitopes of cancers: looking back, looking ahead. Cancer Immunol Res. 2015;3(9):969–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1):128.

Article  PubMed  PubMed Central  Google Scholar 

Tsao SW, Tramoutanis G, Dawson CW, Lo AKF, Huang DP. The significance of LMP1 expression in nasopharyngeal carcinoma. Cancer Biol. 2002;12:473–87.

Article  CAS  Google Scholar 

Yarchoan M, Gane E, Marron TU, Rochestie S, Cooch N, Peters J, et al. Personalized DNA neoantigen vaccine in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma. J Clin Oncol. 2021;39(15):2680.

Article  Google Scholar 

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240–5.

Article  ADS  CAS  PubMed  Google Scholar 

Flores JE, Thompson AJ, Ryan M, Howell J. The global impact of hepatitis B Vaccination on hepatocellular carcinoma. Vaccines (Basel). 2022;10(5):793.

Article  PubMed  Google Scholar 

Chang MH. Hepatitis B virus and cancer prevention. Recent Results Cancer Res. 2011;188:75–84.

Article  CAS  PubMed  Google Scholar 

Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Sm Lin, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348–55.

Article  CAS  PubMed  Google Scholar 

Li Y, Xu C. Human papillomavirus-related cancers. Adv Exp Med Biol. 2017;1018:23–34.

Article  CAS  PubMed